• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, August 25, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Plant-based products are not lowering blood pressure

Bioengineer by Bioengineer
July 16, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: University of Houston

In the high-pressure world of lowering hypertension, a surprising favorite isn't standing up too well in clinical trials.

"Plant products per se or traditional antioxidants like vitamins failed to have a positive impact on renal or cardiovascular health during clinical studies," said Mustafa F. Lokhandwala, UH College of Pharmacy executive vice dean for research and director of the UH Heart and Kidney Institute. Plant-based products include chemical supplements like resveratrol, sulforaphane and curcumin.

So instead of relying on similar outward cures, Lokhandwala and Anees Banday, research associate professor of pharmacology, are looking inward, where they have found that a peptide, Angiotensin 1-7, that humans already possess can relieve oxidative stress and drive blood pressure back into normal ranges. Their hypothesis is backed by $2.64 million from the National Heart, Lung, and Blood Institute.

High blood pressure is a common condition that can cause uncommon damage. With each beat of the heart, blood is pushed through arteries to the rest of the body. That's force, or pressure. If that pressure is too high, either because of the amount of blood the heart pumps or the amount of resistance to pumping it, health problems including heart disease and stroke can occur.

It is well known that kidneys, or the renal system, regulate sodium and blood pressure. "Studies from our lab and others show that renal-specific oxidative stress could be an independent risk factor for systemic hypertension," said Lokhandwala. Oxidative stress is an imbalance between the production of free radicals (unstable atoms that can damage cells) and the body's ability to counteract their threats.

In the kidneys, oxidative stress could cause high blood pressure mostly through poor sodium regulation.

Since its discovery in 1988, the Angiotensin 1-7 peptide has been linked to protective roles in cardiovascular disease and in the health of the kidney, brain and other organs. Lokhandwala and Banday collected experimental evidence to suggest Angiotensin 1-7 could protect kidney cells from oxidative stress and reduce blood pressure.

Eventually, a pill that could activate Angiotensin 1-7 signalling will be a better alternative to currently available medication, said Lokhandwala.

If Angiotensin 1-7 is found to be effective, it will avoid many of the side effects which limit the use of existing drugs.

"Today in hypertension treatment, effective therapy is important, but therapy with fewer side effects would be a plus," said Lokhandwala. "Also, drugs to which patients do not develop tolerance is an important issue."

###

Media Contact

Laurie Fickman
[email protected]
713-743-8454
@UH_News

http://www.uh.edu/news-events

Original Source

http://www.uh.edu/news-events/stories/2018/july-2018/071618.php

Share12Tweet8Share2ShareShareShare2

Related Posts

SPOP drives ZMYND8 ubiquitination, phase-separation loss and mTOR resistance in kidney cancer

August 25, 2026

NF-κB–TNFAIP3 Pathway Alleviates MASLD by Activating Autophagy in Liver Cells

August 25, 2026

Elevated Bilirubin Levels Affect Premature Infants

August 25, 2026

Trace Elements Guide Exosome Modules and Self-Adapting Hydrogels for Diabetic Foot Regeneration

August 25, 2026
Please login to join discussion

POPULAR NEWS

  • Targeting POLG Weakens Breast Cancer Stemness by Disrupting Mitochondrial Function

    29 shares
    Share 12 Tweet 7
  • SPOP drives ZMYND8 ubiquitination, phase-separation loss and mTOR resistance in kidney cancer

    29 shares
    Share 12 Tweet 7
  • Standardized Preclinical Hypothermia Could Advance Neuroprotection for Newborns

    29 shares
    Share 12 Tweet 7
  • NF-κB–TNFAIP3 Pathway Alleviates MASLD by Activating Autophagy in Liver Cells

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Targeting POLG Weakens Breast Cancer Stemness by Disrupting Mitochondrial Function

SPOP drives ZMYND8 ubiquitination, phase-separation loss and mTOR resistance in kidney cancer

Standardized Preclinical Hypothermia Could Advance Neuroprotection for Newborns

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.